Applicant, as named in the Orange Book
Genentech Inc
Next listed expiry: Rozlytrek on 20 Oct 2030. 8 products with live protection, 0 without.
Products with listed protection
| Drug | Earliest generic entry |
|---|---|
| Rozlytrek NDA 218550 entrectinib | 20 Oct 2030 exclusivity |
| Cotellic NDA 206192 cobimetinib fumarate | 30 Dec 2036 patent |
| Itovebi NDA 219249 · 2 strengths inavolisib | 14 Jun 2038 patent, carve-out possible |
| Rozlytrek NDA 212725 · 2 strengths entrectinib | 18 Jul 2038 patent |
| Xofluza NDA 210854 · 2 strengths baloxavir marboxil | 9 Oct 2039 patent |
| Evrysdi NDA 219285 risdiplam | 15 Apr 2041 patent |
| Evrysdi NDA 213535 risdiplam | 15 Apr 2041 patent |
| Xofluza NDA 214410 · 3 strengths baloxavir marboxil | 21 Apr 2041 patent |